



## WHO ARE THE MEMBERS IN SICA-HF?

### 8 European partners

Charité – Universitätsmedizin Berlin (Germany), University of Hull (United Kingdom), Wrocław Medical University (Poland), IRCCS San Raffaele Pisana (Italy), Medizinische Hochschule Hannover (Germany), GABO:mi Gesellschaft für Ablauforganisation :milliarium mbH & Co. KG (Germany), University Clinic of Respiratory and Allergic Diseases Golnik (Slovenia), Silesian Centre for Heart Diseases (Poland)

### 4 Russian partners

V.A. Almazov Federal Center for Heart, Blood & Endocrinology (St. Petersburg), M.V. Lomonosov Moscow State University (Moscow), Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences (Tomsk), Russian Cardiology Research and Production Complex (Moscow)

## WHO ARE THE KEY CONTACTS IN SICA-HF?

### Coordinator

Charité – Universitätsmedizin Berlin, Prof. Stefan D. Anker

### Scientific Coordinator

Charité – Universitätsmedizin Berlin, Dr. Stephan von Haehling

### Coordinator Russia

V.A. Almazov Federal Center for Heart, Blood & Endocrinology, Prof. Evgeny V. Shlyakhto

### Scientific Coordinator Russia

V.A. Almazov Federal Center for Heart, Blood & Endocrinology, Prof. Andrey Zaritskey

### Project Office

GABO:milliarium mbH & Co. KG, Munich, Annina Sorgner

### EC Scientific Officer

Virginija Dambrauskaitė, European Commission, Directorate Research

[www.sica-hf.com](http://www.sica-hf.com)



## SICA-HF

### Studies Investigating Co-morbidities Aggravating Heart Failure



## WHAT IS SICA-HF?

SICA-HF – Studies Investigating Co-morbidities Aggravating Heart Failure – is a collaborative project with partners across Europe and the Russian Federation. The aim of the research is to provide detailed characteristics of the patients with heart failure and co-morbidities (obesity, cachexia and type 2 diabetes) in order to provide a basis for improving the outcomes of the affected patients.

Heart failure means that the heart muscle has either become weak or stiff or that the heart is in the wrong rhythm or the heart valves are not working properly. Sometimes many of these things can go wrong at the same time. It is important to know why the heart has failed so that the patient gets the right treatment. This is one of the most important roles of any doctor looking after a patient with heart failure. We now have very effective treatments for correcting abnormal heart rhythms or valve problems for many patients. Treating heart muscle disease is proving more challenging. Treatment of heart failure due to heart muscle disease is not usually curable, but treatment can slow, stop and sometimes reverse its progression.

Heart failure is usually associated with other medical conditions (co-morbidities) but, until now, attention has focused solely on treating the heart rather than on the associated medical problems. This is the first, internatio-

nal research project to focus on co-morbidities associated with heart failure, with particular emphasis on diabetes and weight problems (both excess weight and weight loss). Treating these associated problems is not only worthwhile in their own right but might also improve the heart failure itself.

The SICA-HF Consortium will integrate research from basic science laboratories, hospital clinics, clinical research laboratories and health-care companies in order to translate research findings both from the laboratory to the clinic and from the clinic back to the laboratory (bi-directional translational science). This research will inform management guidelines and improve treatment.

## WHO SUPPORTS SICA-HF?

SICA-HF is a collaborative research project funded by the European Community's Seventh Framework Programme (FP7 / 2007-2013) under Grant Agreement N° 241558.



## KEY DATA FOR SICA-HF:

<b>Start date:</b>	1 October 2009
<b>Project Duration:</b>	4 years
<b>Funding for 8 European partners:</b> (by European Commission)	3 million €
<b>Funding for 4 Russian partners:</b> (by Russian Ministry)	72 million RUB (≈ 1,6 million €)
<b>Number of patients to be recruited:</b>	2.000